News thumbnail
Health / Wed, 18 Nov 2026 PLOS

Preclinical safety evaluation of Vernolac, a commercially available polyherbal nutraceutical comprising Vernonia zeylanica, Nigella sativa, Hemidesmus indicus, Smilax glabra, and Leucas zeylanica, in

Vernolac is a commercially available polyherbal formulation comprising Vernonia zeylanica aerial parts, Nigella sativa seeds, Hemidesmus indicus roots, Smilax glabra rhizome, and Leucas zeylanica aerial parts. For the acute toxicity study, consumption data were summarized over the post-administration observation period, whereas for the 28-day repeated-dose toxicity study, weekly consumption values and overall mean daily consumption were calculated. Similar to the acute toxicity study, males and females were housed separately in cages containing five animals each. Histopathological evaluation following acute Vernolac administration demonstrated preserved architecture of the liver, spleen, kidneys, lungs, heart, and brain in both sexes. Additionally, based on the available acute toxicity data, the substance may be considered to fall within the lower acute toxicity hazard categories under the GHS classification system [38,39].

Vernolac is a commercially available polyherbal formulation comprising Vernonia zeylanica aerial parts, Nigella sativa seeds, Hemidesmus indicus roots, Smilax glabra rhizome, and Leucas zeylanica aerial parts. Although previous in vitro studies have demonstrated the anticancer potential of Vernolac and its active ingredients, safety data are available only for some of the plant ingredients of Vernolac. In the present study, acute and 28-day repeat-dose toxicity of Vernolac were evaluated in Wistar rats in accordance with OECD guidelines 420 and 407, respectively. Acute toxicity was investigated for 14 days after administering a single oral dose of 2000 mg/kg to 10 animals (5 males, 5 females). A repeat-dose toxicity study was conducted, in which the human equivalent therapeutic dose in rats (HED; 165 mg/kg/day), a mid-dose (2 × HED; 330 mg/kg/day), and a high dose (4 × HED; 660 mg/kg/day) were administered to three separate groups, each comprising 10 naive animals (5 males and 5 females), for a period of 28 days. In both acute and repeat-dose studies, no morbidity, mortality, changes in food and water intake, relative organ weights, microscopic changes in organs, hematological changes, or clinical signs of toxicity were observed. In the acute study, a significant increase in AST and ALT levels was observed in males. In the 28-day repeated dose study, a significant reduction in ALT was observed only in females receiving 4x HED. In summary, the LD 50 of Vernolac is above 2000 mg/kg, and a dose up to two times the therapeutic daily dose is non-toxic in Wistar rats over 28 days. The liver may be a target organ of toxicity when overdosed.

Data Availability: All data underlying the findings of this study are fully available without restriction and are contained within the manuscript.

Copyright: © 2026 Wijerathne et al. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Accordingly, the present study was designed to systematically evaluate the safety of Vernolac through acute and 28-day repeat dose oral toxicity studies in Wistar rats. The findings of this study aim to establish critical safety parameters, including NOAEL and OELs, thereby providing foundational evidence to support the safe use of Vernolac as a nutraceutical and to inform the design of subsequent long-term and efficacy-focused investigations in cancer research.

Furthermore, the availability of robust toxicological data is essential to support future in vivo efficacy studies, including xenograft cancer models, by enabling differentiation between adverse effects attributable to tumor burden and those arising from formulation-related toxicity [ 23 ]. In accordance with OECD guidelines for the testing of chemicals and herbal products, a structured evaluation comprising acute and repeated-dose oral toxicity studies provides a scientifically and ethically justifiable framework for safety assessment.

In vivo toxicity studies are therefore warranted to validate the safety of Vernolac as a polyherbal formulation and to strengthen the scientific evidence supporting its use. Acute oral toxicity testing provides essential information on immediate toxic effects following a single high-dose exposure, while repeated-dose (subacute/chronic) toxicity studies enable the identification of target organ toxicity, cumulative adverse effects, and safe dose limits relevant to prolonged use. Such data are particularly crucial for nutraceuticals like Vernolac, which are intended for repeated administration as supportive therapies in chronic disease settings, including cancer.

However, a critical knowledge gap remains, as the safety profile of Vernolac as a combined polyherbal formulation has not been previously evaluated in vivo. Importantly, the cytotoxic and antiproliferative effects reported for this formulation and its individual components are dose-dependent, underscoring the need to distinguish therapeutic efficacy from potential toxicity.

A recent study demonstrated that a supercritical CO 2 extract of Vernolac exhibits potent and selective anticancer activity against cancer stem cell–like NTERA-2 cl.D1 cells, inducing apoptosis, oxidative stress, and suppression of migration while sparing non-cancerous cells, thereby supporting its potential as a targeted anticancer nutraceutical [ 18 ]. An integrative network pharmacology and in vitro study revealed that Vernolac contains multiple bioactive phytochemicals targeting key cancer-related pathways, with predicted actions involving apoptosis induction, immune modulation, and antiproliferative mechanisms [ 22 ].

A polyherbal decoction consisting of N. sativa seeds, H. indicus roots, and S. glabra rhizomes in equal proportions has been traditionally prescribed for the management of cancer by a lineage of Ayurvedic physicians in Sri Lanka, underscoring its long-standing ethnopharmacological significance in oncology [ 19 ]. Previous studies have demonstrated that this decoction confers marked protection against chemically induced hepatocarcinogenesis in rat models, with no evidence of significant toxicity [ 20 , 21 ]. Additionally, the formulation has demonstrated notable cytotoxic activity against human hepatoma (HepG2) cells in vitro [ 19 , 20 ].

Vernolac is a polyherbal nutraceutical capsule manufactured by Fadna Life Sciences (Pvt) Ltd (106/6B, Araliya Uyana, Depanama, Pannipitiya, Sri Lanka), currently available in the Sri Lankan market for the management of cancer. The formulation comprises five medicinal plants with ethnomedical relevance, namely Vernonia zeylanica (aerial parts), Nigella sativa (seeds), Smilax glabra (rhizome), Leucas zeylanica (aerial parts), and Hemidesmus indicus (roots). The formulation is currently used alongside conventional cancer therapies, with claims related to supporting anticancer activity, reducing oxidative stress, and improving patient well-being during long-term treatment [ 17 , 18 ].

Recent recommendations emphasize the importance of clear verification of plant medicines and nutraceuticals for the identity, source, composition and quality of the test material along with appropriate chemical characterization and preclinical safety assessment. This is due to the multiple bioactive constituents in such plant material may vary according to many factors including plant source, storage conditions and processing and manufacturing methods. Therefore adequate characterization is essential in order to ensure the reproducibility and interpretation of toxicological findings. Recent studies in toxicity also states the need of considering adverse effects, variability and stability in products and, plant-drug or plant-plant interactions in order to evaluate safety of complex plant and nutraceutical products [ 14 – 16 ].

However, this same complexity raises safety concerns, as interactions among bioactive phytochemicals can alter pharmacological and toxicological profiles in ways that cannot be predicted from studies of individual plant constituents [ 10 , 11 ]. Therefore, regulatory authorities and international guidelines emphasize the necessity of rigorous preclinical safety evaluation of herbal formulations, especially those intended for repeated or prolonged human consumption [ 12 , 13 ].

Nutraceuticals have emerged as promising adjuncts to conventional anticancer therapies due to their ability to enhance therapeutic outcomes and reduce side effects [ 7 ]. The anticancer potential of nutraceuticals is attributed to their potential to target diverse molecular mechanisms associated with carcinogenesis, such as uncontrolled cell proliferation, apoptosis, angiogenesis, and inflammation [ 7 , 8 ]. Beyond these effects, they can reduce oxidative stress, protect against genomic damage, modulate epigenetic processes, restore tumor suppressor activity, and enhance immune surveillance. Furthermore, growing research highlights their capacity to influence the gut microbiome, an important regulator of host immunity and inflammatory responses [ 8 , 9 ]. Polyherbal nutraceutical formulations are of particular interest due to their multi-component and multi-target nature, which may enhance therapeutic efficacy through synergistic mechanisms [ 7 , 8 ].

Natural products have attracted considerable interest in the field of cancer therapy owing to their wide-ranging therapeutic potential [ 5 , 6 ]. A diverse array of bioactive compounds sourced from plants, marine organisms, fungi, and microorganisms has demonstrated anticancer activity through the regulation of critical cellular pathways, including apoptosis, cell proliferation, angiogenesis, and immune modulation [ 5 ].

Cancer continues to be a major global health challenge and remains among the leading causes of mortality worldwide [ 1 , 2 ]. Despite substantial advances in early diagnostic techniques and therapeutic interventions, the overall burden of cancer is steadily increasing [ 3 ]. Conventional treatment modalities, including surgery, chemotherapy, radiotherapy, and targeted therapies, constitute the cornerstone of cancer management; however, their clinical utility is often limited by significant adverse effects [ 3 , 4 ]. In addition, the development of therapeutic resistance poses a major obstacle, frequently resulting in disease progression and treatment failure [ 4 ]. Collectively, these limitations highlight the critical need for innovative cancer therapies that are both efficacious and better tolerated.

For the acute oral toxicity study, quantitative data from Vernolac-treated animals were compared with the corresponding sex-matched vehicle-control group using an independent-samples t-test. For the 28-day repeated-dose toxicity study, differences among groups were evaluated using one-way analysis of variance (ANOVA), followed by Dunnett’s multiple-comparisons test to compare each Vernolac-treated group (165, 330, and 660 mg/kg/day) directly with the corresponding vehicle-control group.

Histopathological examination was performed by an experienced pathologist who was blinded to the treatment groups during the evaluation to minimize potential observer bias. Histopathological findings in Vernolac-treated animals were compared with those observed in the corresponding sex-matched vehicle control animals to identify treatment-related lesions or pathological changes.

The stained sections were examined using a light microscope (Olympus BX43, Olympus Corporation, Japan) for evidence of treatment-related histopathological alterations. Tissue architecture and cellular morphology were systematically evaluated, with particular attention to degenerative, inflammatory, necrotic, vascular, and other pathological changes, where applicable.

Histopathological examination was performed on the collected organs from all animals included in both the acute and 28-day repeated-dose toxicity studies. Following fixation, tissue samples were processed using routine histological procedures, dehydrated through graded concentrations of alcohol, cleared, and embedded in paraffin wax. Paraffin-embedded tissues were sectioned at approximately 4 μm thickness and stained with hematoxylin and eosin (H&E) for microscopic evaluation.

Serum biochemical parameters were measured using a calibrated automated chemistry analyzer (AS-280, E-Lab Biological Science & Technology Co., Ltd., China) according to the manufacturer’s analytical procedures. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities were determined as biochemical markers of hepatocellular injury, whereas serum urea and creatinine concentrations were measured as indicators of renal functional status.

Following weighing and gross examination, the collected organs and tissues were immediately immersed in 10% neutral-buffered formalin for subsequent histopathological evaluation. An adequate volume of fixative was used to ensure complete tissue immersion and effective fixation, with an approximate tissue-to-fixative volume ratio of 1:8. Fixed tissues were subsequently processed for routine histopathological examination as described in the relevant section.

The liver, kidneys, adrenal glands, brain, heart, lungs, and spleen were carefully excised, cleared of adhering connective tissue as appropriate, and examined macroscopically. Wet organ weights were recorded immediately following dissection to minimize changes associated with tissue dehydration. Relative organ weight was calculated using the following equation:

Approximately 3–5 mL of blood was collected from each animal by cardiac puncture for hematological and serum biochemical analyses. Approximately 1 mL of whole blood was transferred into ethylenediaminetetraacetic acid (EDTA) containing tubes and used for hematological evaluation. Approximately 2.5 mL of blood was collected into plain tubes for serum biochemical analysis. Samples collected into plain tubes were allowed to clot at room temperature and subsequently centrifuged at 2500 rpm for 10 min at room temperature. The resulting serum was carefully separated and retained for biochemical analyses.

At the termination of the experimental period, animals were subjected to terminal procedures using carbon dioxide (CO 2 ) inhalation in a designated euthanasia chamber. CO 2 was introduced gradually until the animals became unconscious and reached a deep plane of terminal anesthesia. Once deep anesthesia was established, blood was collected by terminal cardiac puncture. CO 2 exposure was subsequently continued until respiratory arrest and maintained for at least 1 min thereafter to ensure death. The absence of spontaneous respiration and other signs of life was confirmed before the animals were removed for necropsy. Animals showing any residual signs of life were re-exposed to CO 2 until death was unequivocally confirmed.

As only one cage was available per sex and treatment group in both studies, food and water consumption data were evaluated descriptively without inferential statistical comparisons to avoid pseudoreplication, consistent with the cage-based descriptive reporting approach employed by Greiser et al. [ 26 ].

For the acute toxicity study, consumption data were summarized over the post-administration observation period, whereas for the 28-day repeated-dose toxicity study, weekly consumption values and overall mean daily consumption were calculated.

Normalized food and water consumption were expressed as g/100 g body weight/day and mL/100 g body weight/day, respectively. As body weights were recorded periodically, consumption was normalized using the corresponding body-weight measurements for each observation period.

Food and water consumption were monitored during both the acute and 28-day repeated-dose oral toxicity studies. Food and water consumption were measured daily at the cage level by determining the difference between the quantities provided and those remaining after 24 h. Total daily food and water consumption were expressed as g/cage/day and mL/cage/day, respectively. Average daily consumption per animal was calculated by dividing the total cage consumption by the number of animals housed in the cage. To account for variations in body weight during the observation periods, food and water consumption were further normalized to 100 g body weight using the combined body weight of the animals in the respective cage, as follows:

Recovery (satellite) groups were not included in the present study. According to OECD Test Guideline 407, recovery groups may be incorporated when considered necessary to assess the persistence, reversibility, or delayed occurrence of toxic effects. In this study, recovery groups were not included because the primary objective was to evaluate the toxicological effects of Vernolac following 28 days of continuous administration. The study design also considered the principles of the 3Rs by avoiding the use of additional animals unless scientifically necessary [ 25 ].

Food and water consumption were measured daily on a cage basis. Body weight was recorded prior to the initiation of treatment and at weekly intervals thereafter. Further, the animals were monitored daily during the experimental period for mortality, signs of toxicity, and behavioral changes as specified in the section ‘Acute toxicity study’. On Day 29, following completion of the 28-day treatment period, rats were sacrificed, and blood and organ samples were collected as described in the section ‘Euthanizing, autopsy, and sample collection’.

Group I served as the vehicle control and received distilled water, whereas Groups II, III, and IV received Vernolac as a freshly prepared aqueous suspension at dose levels of 165, 330, and 660 mg/kg body weight/day, respectively. The test formulation or vehicle was administered orally once daily at approximately the same time each day for 28 consecutive days.

The repeated-dose 28-day oral toxicity study was conducted in accordance with the OECD Test Guideline 407. A total of 40 healthy Wistar rats, comprising 20 males and 20 females, were used in the study. Following acclimatization, animals were randomly allocated, into four experimental groups. Each group consisted of 10 animals, comprising five males and five females. Similar to the acute toxicity study, males and females were housed separately in cages containing five animals each. Therefore, each treatment group consisted of two cages, one for males and one for females, resulting in a total of eight cages in the 28-day repeated-dose toxicity study.

Clinical observations included mortality, morbidity, behavioral abnormalities, and other signs indicative of systemic toxicity. Particular attention was given to changes in vocalization, chromodacryorrhea, eye squinting, respiratory pattern, appearance of the nose and cheeks, ears and whiskers, posture, locomotor activity, piloerection, grooming behavior, fecal consistency, gait, nasal and ocular discharge, seizures, and salivation. Body weights were recorded prior to dosing and at weekly intervals throughout the 14-day observation period, and on the day of sacrifice using a calibrated sensitive balance. Food and water consumption were monitored daily on a cage basis. At the end of the observation period (15 th day), all surviving animals were euthanized and subjected to terminal sampling. Blood samples and organs were collected for subsequent hematological, biochemical, and histopathological evaluations as described in Section ‘Euthanizing, autopsy, and sample collection’.

Following administration, food was withheld for an additional 3 h, while access to drinking water was maintained. Animals were individually observed closely during the initial post-dosing period at approximately 10 min, 30 min, 1 h, 2 h, 4 h, and 6 h after administration and subsequently at least once daily for a total observation period of 14 days.

Prior to the treatment, the animals were acclimatized to the experimental conditions for 14 days with free access to standard laboratory feed and drinking water. At the end of the acclimatization period, animals were fasted overnight while water remained available ad libitum. The rats were then randomly allocated, into two groups of 10 animals each, consisting of five males and five females per group. Male and female rats were housed separately, with five animals of the same sex accommodated in each cage. Accordingly, each treatment group consisted of two cages, one containing five male rats and the other containing five female rats, resulting in a total of four cages in the acute toxicity study. The vehicle control group received distilled water, whereas the treatment group received Vernolac as a freshly prepared aqueous suspension at a single oral dose of 2000 mg/kg body weight.

The acute oral toxicity study was conducted with reference to the Organisation for Economic Co-operation and Development (OECD) Guideline 420 (Fixed Dose Procedure), with slight modifications to the standard protocol. A total of 20 healthy Wistar rats (10 males and 10 females) were included in the study. Both male and female animals were utilized to evaluate potential sex-dependent variations. Sex-matched vehicle control groups were included to enable valid comparisons between Vernolac-treated and control animals.

Although Vernolac is commercially available in capsule form, the formulation used in the present study was supplied directly by Fadna Life Sciences (Pvt) Ltd. as the capsule-fill formulation without the capsule shell. The required amount of the formulation was weighed according to the intended dose and freshly suspended in distilled water before administration. Fresh aqueous suspensions of Vernolac were prepared daily throughout the treatment period and thoroughly mixed to ensure a uniform dispersion of the herbal components. The freshly prepared suspensions were administered orally by gavage at the calculated dose volumes.

Utilizing Km values of 37 and 6 in humans and rats, respectively. Accordingly, the calculated rat equivalent dose was 164.5 mg/kg/day, which was approximated to 165 mg/kg/day and considered as the lowest dose. To assess potential dose-dependent toxicological effects, subsequent doses of 330 and 660 mg/kg/day were selected as two-fold and four-fold multiples of the lowest dose (165 mg/kg/day).

For the acute toxicity study, a single predefined dose of 2000 mg/kg body weight was administered. The lowest dose selected for the 28-day repeated-dose toxicity study was based on the recommended human daily intake of Vernolac (1600 mg/day). The human daily dose was converted to a corresponding rat dose using body surface area (BSA) normalization and species-specific Km factors, as described in established interspecies dose-conversion methods [ 24 ]. Assuming an average adult body weight of 60 kg, the recommended human dose of 1600 mg/day corresponds to 26.67 mg/kg/day. The corresponding rat dose was calculated using the following equation:

Healthy albino Wistar rats of either sex, 8–12 weeks of age, weighing 179 ± 20 g, were purchased from Medical Research Institute, Colombo, Sri Lanka. The female rats were nulliparous and non-pregnant. The animals were maintained under standard laboratory conditions (25 °C ± 2 °C, 12 h/12 h light/dark cycle, 40% − 70% relative humidity) in polypropylene cages, and had free access to standard pellet diet and water ad libitum. The protocol used in the study was approved by the Institute of Biology, Sri Lanka (ERC IOBSL 386/12/2024). All the animals were acclimatized for two weeks before the start of the experiment.

The Vernolac formulation was subjected to gas chromatography–mass spectrometry (GC–MS) analysis to establish its chemical fingerprint and characterize the phytochemical constituents present in the formulation. The detailed analytical methodology and identified compounds have been previously reported by Vass Gunawardane et al. [ 22 ]. Since GC–MS profiling detects only compounds amenable to this analytical technique, the identified compounds represent a subset of the phytochemical constituents present in the formulation rather than the complete phytochemical composition of Vernolac. As part of the quality control evaluation of Vernolac, each production batch is subjected to cytotoxicity testing using a validated in vitro assay to evaluate potential cytotoxic effects and support batch-to-batch quality consistency.

Vernolac is a commercially available polyherbal nutraceutical capsule formulated from standardized herbal ingredients, including the aerial parts of V. zeylanica, seeds of N. sativa, roots of H. indicus, rhizomes of S. glabra, and aerial parts of L. zeylanica. The formulation was manufactured and supplied by Fadna Life Sciences (Pvt) Ltd., Sri Lanka (106/6B, Araliya Uyana, Depanama, Pannipitiya, Sri Lanka). The study utilized Vernolac formulation from batch number V240825, manufactured on August 25, 2024 with an expiry date of August 25, 2025. The formulation was stored under recommended storage conditions in a cool and dry environment at temperatures below 30°C until further use.

Brain sections from all groups demonstrated preserved neuronal architecture with no detectable microscopic alterations. Overall, histopathological evaluation of the examined organs following 28-day repeated oral administration of Vernolac revealed no treatment-related pathological changes, supporting the absence of target-organ toxicity under the conditions of the study.

Microscopic examination of lung tissues revealed normal pulmonary architecture in both control and Vernolac-treated groups, with no observable lesions including inflammatory infiltration, edema, congestion, or structural disruption. Heart sections showed preserved myocardial architecture without evidence of degeneration, necrosis, inflammatory changes, or other treatment-related abnormalities.

Liver sections from control and Vernolac-treated animals demonstrated preserved hepatic architecture with normal hepatocyte morphology and arrangement. No evidence of hepatocellular degeneration, necrosis, inflammatory cell infiltration, congestion, or other treatment-related hepatic lesions was observed. The spleen exhibited normal structural organization with intact red and white pulp compartments, without evidence of lymphoid depletion, congestion, or other pathological changes.

Fig 3. Histopathological images of organs (liver, spleen, kidney, lung, heart, and brain) of male rats in the 28-day repeated dose toxicity study treated with Vernolac at doses 165 mg/kg, 330 mg/kg, 660 mg/kg/day, and the control group stained with hematoxylin and eosin (H&E) at 400x magnification.

Fig 2. Histopathological images of organs (liver, spleen, kidney, lung, heart, and brain) of female rats in the 28-day repeated dose toxicity study treated with Vernolac at doses 165 mg/kg, 330 mg/kg, 660 mg/kg/day and the control group stained with hematoxylin and eosin (H&E) at 400x magnification.

Figs 2 and 3 illustrate the representative histopathological findings of organs collected from female and male rats, respectively, following 28 days of repeated oral administration of Vernolac at 165, 330, and 660 mg/kg/day. Histopathological examination of the liver, spleen, kidneys, lungs, heart, and brain from all Vernolac-treated groups revealed no treatment-related microscopic alterations compared with the respective vehicle-control groups.

Fig 1 illustrates the representative histopathological findings of major organs collected from control and Vernolac-treated animals in the acute oral toxicity study. Microscopic examination revealed no treatment-related histopathological alterations following a single oral administration of Vernolac at 2000 mg/kg. Liver sections demonstrated preserved hepatic architecture with normal hepatocyte morphology and arrangement, without evidence of hepatocellular degeneration, necrosis, inflammatory cell infiltration, or vascular congestion. The spleen exhibited normal structural organization with intact red and white pulp compartments. Kidney sections showed preserved renal architecture, including normal glomeruli, renal tubules, and interstitial structures, with no observable signs of tubular degeneration, inflammation, or fibrosis. Furthermore, lung, heart, and brain tissues maintained normal microscopic architecture without detectable treatment-related lesions.

Histopathological evaluation was performed on the liver, spleen, kidneys, lungs, heart, and brain collected from all animals included in both the acute oral toxicity study and the 28-day repeated-dose oral toxicity study. Tissue sections were stained with hematoxylin and eosin (H&E) and examined microscopically for treatment-related structural alterations. Microscopic examination was performed on tissues collected from all animals in each experimental group. Histopathological findings were evaluated and compared across treatment and corresponding control groups. Representative photomicrographs were selected to illustrate the characteristic microscopic findings observed in each group.

In female rats ( Table 15 ), no statistically significant treatment-related alterations were observed in the evaluated hematological or biochemical parameters compared with the respective vehicle-control group, except for MCH and ALT, which showed significant changes only at the highest dose level. In male rats ( Table 16 ), no statistically significant differences were observed in WBC, neutrophils, lymphocytes, monocytes, basophils, RBC, or MCHC when compared with the control group. A significant reduction in eosinophil percentage was observed in all Vernolac-treated groups, with eosinophil levels becoming undetectable at the highest dose level. Statistically significant variations were observed in hemoglobin, HCT, MCV, MCH, and platelet counts in male rats. However, these changes were not associated with a consistent dose-dependent pattern, and the observed values remained within reported physiological reference ranges for laboratory rats.

Relative organ weights of major organs from male and female rats administered Vernolac at doses of 165, 330, and 660 mg/kg/day for 28 consecutive days were compared with those of the respective vehicle-control groups. No statistically significant differences were observed in the relative weights of examined organs in either sex at any dose level (p > 0.05; Tables 13 and 14 ). No dose-dependent alterations in organ weights were evident following Vernolac administration.

Food and water consumption showed weekly variations in both male and female rats, without a consistent dose-dependent pattern. However, slightly lower food and water consumption was observed in males treated with 660 mg/kg compared with the control group ( Tables 11 and 12 ). As consumption was measured at the cage level, the data were evaluated descriptively without inferential statistical comparisons.

Body weights of male and female rats in the control and Vernolac-treated groups (165, 330, and 660 mg/kg/day) were monitored throughout the treatment period. Minor fluctuations in body weight were observed in all groups; however, no statistically significant differences (p > 0.05) were detected between control and treated females at any dose level ( Table 9 ). In male rats ( Table 10 ), a statistically significant difference in overall mean body weight was observed between the control and 165 mg/kg/day groups (p = 0.0092). The 165 mg/kg/day group had a higher overall mean body weight than the control group. However, no statistically significant differences were observed between the control and 330 mg/kg/day groups or between the control and 660 mg/kg/day groups.

The daily oral administration of Vernolac at doses of 165, 330, and 660 mg/kg/day for 28 consecutive days did not result in any adverse symptoms, mortality, or abnormal clinical signs ( Table 8 ).

With respect to serum biochemical parameters, statistically significant increases in AST (p = 0.0068) and ALT (p = 0.0384) were observed in male rats treated with Vernolac compared with the corresponding vehicle-control group. No statistically significant alterations were observed in the other biochemical parameters evaluated. According to the acute study findings, the LD 50 for Vernolac is greater than 2000 mg/kg.

No mortality, treatment-related clinical signs, or abnormal behavioral changes were observed in Vernolac-treated animals throughout the 14-day observation period ( Table 1 ). No statistically significant differences (p > 0.05) were detected between the treated and vehicle-control groups in body weight ( Tables 2 and 3 ), relative organ weights ( Tables 4 and 5 ), or hematological and biochemical parameters ( Tables 6 and 7 ). Food and water consumption in Vernolac treated rats (2000 mg/kg) remained generally comparable to controls, with minor sex-specific variations ( Tables 2 and 3 ).

The acute toxicity of Vernolac was determined in accordance with OECD Guideline 420. Oral administration of Vernolac at a single dose of 2000 mg/kg was evaluated for treatment-related toxicity symptoms or mortality during the first six hours, and then daily for a period of 14 days.

Discussion

Vernolac is a commercially available polyherbal formulation used in supportive cancer therapy comprising of aerial parts of V. zeylanica, seeds of N. sativa, roots of H. indicus, rhizomes of S. glabra, and aerial parts of L. zeylanica. The therapeutic rationale for this formulation is supported by increasing preclinical evidence demonstrating anticancer and cancer-supportive activities of the complete formulation, related polyherbal combinations, individual constituent plants, and their bioactive phytochemicals [12,13,17–22]. Recent investigations have demonstrated promising anticancer properties of Vernolac. A supercritical CO 2 extract of Vernolac exhibited cytotoxic activity against cancer stem-like NTERA-2 cl. D1 cells, with an IC₅₀ of 41.12 µg/mL after 48 h of exposure [18]. The anticancer response was associated with induction of apoptosis, increased intracellular reactive oxygen species, inhibition of cellular migration, activation of caspase-3/7, upregulation of TP53, and downregulation of Survivin and mTOR [18]. These observations indicate that Vernolac may influence several molecular pathways relevant to cancer cell survival and proliferation.

Network pharmacology-based investigations have further suggested that Vernolac may exert biological effects through interconnected mechanisms involving apoptosis, immune modulation, anti-inflammatory activity, suppression of cell proliferation, and modulation of responses to chemotherapy and radiotherapy [22]. The same analysis suggested potential chemo- and radioprotective effects through attenuation of treatment-associated toxicity [22].

The pharmacological rationale for Vernolac is also supported by previous studies of three of its principal botanical components. A decoction containing N. sativa seeds, H. indicus roots, and S. glabra rhizomes produced a marked dose-dependent cytotoxic effect against HepG2 human hepatoma cells, with N. sativa demonstrating the highest cytotoxic activity among the individual extracts, followed by H. indicus and S. glabra [13]. Further investigations demonstrated that this polyherbal decoction induced apoptosis in HepG2 cells, as evidenced by DNA fragmentation, characteristic apoptotic morphological changes, upregulation of the pro-apoptotic gene Bax, downregulation of the anti-apoptotic gene Bcl-2, and time- and dose-dependent activation of caspase-3 and caspase-9 [19,20].

Anti-inflammatory activity has also been demonstrated for the aforementioned decoction. The decoction reduced carrageenan-induced paw edema, suppressed hepatic NF-κB activation through inhibition of IKKα/β, reduced nitric oxide production and leukocyte migration, and exhibited membrane-stabilizing activity [27]. In addition, anticancer activity has been documented for several bioactive compounds isolated from the individual plants incorporated into the formulation [20,28–31]. Collectively, these observations support the biological plausibility of Vernolac as a multi-component formulation with anticancer-related activity, while simultaneously emphasizing the importance of characterizing its toxicological profile.

The present investigation therefore evaluated the in vivo safety of Vernolac using acute and 28-day repeated-dose oral toxicity studies in Wistar rats, within the framework of OECD Test Guidelines 420 (with slight modifications) and 407, respectively. Toxicity studies in experimental animals provide important information regarding potential systemic toxicity, target-organ effects, dose-response relationships, and exposure levels associated with the absence of adverse effects [32]. An integrated interpretation incorporating mortality, clinical observations, body weight, food and water consumption, hematological and biochemical parameters, organ weights, and histopathology provides a more reliable assessment of toxicological relevance than consideration of statistically significant findings in isolation.

The oral acute toxicity of Vernolac was assessed following a single administration at a dose of 2000 mg/kg. Animals were observed for a 14-day period, during which no mortality, treatment-related behavioral changes, or visible signs of toxicity were detected. Body weight, food consumption, water intake, and relative organ weights remained comparable with the respective vehicle-control groups. These findings demonstrate that a single high oral dose of Vernolac was generally well tolerated under the experimental conditions employed. In female Wistar rats, no significant alterations were observed in hematological or biochemical parameters. Similarly, hematological parameters in male rats did not differ significantly from those of the control group. However, serum AST and alanine ALT activities were significantly elevated in male rats compared with controls. Increases in circulating aminotransferases, particularly ALT, may result following hepatocellular membrane injury [33] and therefore require careful toxicological evaluation. AST is less specific to the liver than ALT because it is also present in other tissues, including skeletal and cardiac muscle [34].

In the present study, the acute increases in AST and ALT observed in male rats were not accompanied by changes in relative liver weight or histopathological evidence of hepatocellular degeneration, necrosis, inflammation, vascular injury, or disruption of normal hepatic architecture. Moreover, the observed AST and ALT values remained within the reported historical control ranges for 8–12-week-old Wistar rats [35]. Importantly, the same pattern of increased aminotransferase activity was not reproduced following repeated administration of Vernolac for 28 consecutive days. Taken together, these findings suggest that the acute biochemical changes were transient and were not indicative of persistent structural hepatotoxicity.

The absence of structural hepatic injury is also consistent with previous investigations of the related three-component polyherbal decoction. Iddamaldeniya et al. demonstrated that long-term administration of a decoction containing N. sativa, H. indicus, and S. glabra inhibited diethylnitrosamine-induced hepatocarcinogenesis in male Wistar rats [36]. In that study, treatment for up to 16 months reduced carcinogen associated hepatic alterations and prevented the development of overt tumors and histopathological changes associated with hepatocarcinogenesis. These previous observations suggest that these botanical components are not intrinsically associated with progressive hepatic injury at the doses evaluated and may possess hepatoprotective or chemopreventive properties under specific experimental conditions.

A separate toxicological investigation of the same three-component decoction provides further supportive evidence. In addition, no mortality or clinical signs of toxicity were observed even at an extremely high dose level of 240 g/kg/day. These findings indicate the absence of observable adverse effects over prolonged exposure and demonstrate a wide margin of safety for the decoction [37]. Moreover, very high exposure to the decoction was reportedly not associated with mortality or overt clinical toxicity. These observations are broadly consistent with the favorable acute and repeated-dose safety profile identified for Vernolac.

Histopathological evaluation following acute Vernolac administration demonstrated preserved architecture of the liver, spleen, kidneys, lungs, heart, and brain in both sexes. No treatment related microscopic lesions were identified in these organs. Taken together with the absence of mortality and overt clinical toxicity at 2000 mg/kg, these findings indicate a low acute oral toxicity potential under the conditions of the present study.

Consequently, the LD 50 of orally administered Vernolac exceeded 2000 mg/kg body weight in both sexes. Under defined test conditions, LD 50 indicates the dose which causes mortality in 50% of animal population exposed to the test substance. LD 50 is an endpoint based on lethality and not indicative of non-lethal biological or physiological effects. OECD guidance on acute oral toxicity testing explicitly distinguishes the dose-response relationship for lethality from the relationship related to other toxicological signs and the importance of non-lethal toxicity is taken into the account in the process of evaluating acute toxicity. These facts indicate that the absence of mortality at a dose of 2000 mg/kg can conclude that LD 50 is > 2000 mg/kg, however physiological or biochemical effects may still occur at the given dose during the treatment process [38]. Additionally, based on the available acute toxicity data, the substance may be considered to fall within the lower acute toxicity hazard categories under the GHS classification system [38,39].

The 28-day repeated-dose study was performed to characterize potential systemic toxicity following daily oral exposure to Vernolac. Animals received 165, 330, or 660 mg/kg/day for 28 consecutive days. No mortality, treatment-related clinical signs, or overt behavioral abnormalities were observed at any dose level in either sex. The absence of clinical toxicity throughout repeated exposure provides important evidence that Vernolac was generally well tolerated over the study period.

No statistically significant differences in food or water consumption were observed between the control and Vernolac-treated groups in either sex. Alterations in food intake may be associated with factors such as reduced palatability, gastrointestinal disturbances, metabolic changes, or systemic toxicity, whereas changes in water intake may reflect metabolic, renal, or endocrine disturbances. Therefore, the absence of significant treatment-related changes in food and water consumption suggests that Vernolac did not adversely affect these physiological parameters under the conditions of the study.

Although the animals were randomly assigned to the experimental groups before study initiation, some variation in baseline body weights was observed among the male treatment groups. Formal statistical comparisons were not performed at the time of group allocation. However, a subsequent statistical analysis of the raw baseline data revealed a statistically significant reduction in baseline body weight in the 330 mg/kg/day group compared with the control group. In contrast, the mean baseline body weight of the 165 mg/kg/day group was higher than that of the control group, although this difference was not statistically significant. Furthermore, analysis of body-weight changes from baseline to the final observation showed no significant difference between the control and 165 mg/kg/day groups, indicating that the higher baseline body weight in this group was not accompanied by a greater increase in body weight during treatment. Although greater weight gain was observed in the 330 mg/kg/day group, no consistent dose-dependent pattern was evident. Taken together, these findings suggest that the higher body weight observed in the 165 mg/kg/day group may have reflected pre-existing baseline variability rather than a treatment-related increase in body weight.

No significant variations in relative organ weights were observed in either sex at any Vernolac dose. Organ-weight alterations are sensitive indicators of potential target-organ responses and may occur in association with hypertrophy, atrophy, congestion, inflammation, metabolic adaptation, or tissue injury [40]. However, organ-weight changes should be interpreted in conjunction with the corresponding clinical pathology and histopathological findings. In the present study, the absence of relative organ-weight alterations was supported by the intact microscopic architecture of all observed organs with no signs of organ-specific hypertrophy, atrophy or target organ toxicity.

Most hematological parameters remained unaffected following repeated Vernolac administration. In female rats, a statistically significant alteration in MCH was observed only at 660 mg/kg/day. However, the value remained within the established physiological reference range [26,41,42] and was not accompanied by a consistent pattern of alterations in RBC count, hemoglobin concentration, hematocrit, MCV, MCHC, or other erythrocyte indices indicative of anemia or disturbed erythropoiesis. The isolated nature of the finding and absence of corroborating hematological abnormalities suggest limited toxicological significance.

In male rats, statistically significant variations were observed in hemoglobin, HCT, MCH, and platelet counts. However, the values remained within the physiological reference ranges [26,41].

Total WBC count, neutrophils, lymphocytes, monocytes, basophils, RBC count, and MCHC were not significantly affected. Accordingly, the findings do not indicate generalized hematotoxicity following the administration of Vernolac for 28 consecutive days.

The most notable hematological finding was the significant reduction in the percentage of eosinophils in male rats across the Vernolac-treated groups. The eosinophil percentage decreased to undetectable levels (0%) at the highest dose. Eosinophil concentrations may be influenced by numerous physiological factors, including endogenous glucocorticoid activity, diurnal rhythm, stress responses, circadian variation, redistribution of circulating eosinophils, inflammatory status, and immune modulation [43,44]. Importantly, the eosinophil reduction was not accompanied by decreases in total leukocyte counts, neutrophils, lymphocytes, or monocytes, nor were clinical manifestations suggestive of immune dysfunction observed. Histopathological examination of the spleen demonstrated preserved red and white pulp architecture without treatment-related microscopic abnormalities. These findings argue against generalized leukotoxicity or overt structural toxicity to the spleen. Therefore, although the reduction in circulating eosinophils is considered a potentially treatment-associated hematological finding, the available evidence does not establish it as an adverse toxicological effect.

Biochemical evaluation included AST, ALT, blood urea, and serum creatinine as the selected indices reflecting hepatic and renal status. Repeated administration of Vernolac in male rats did not cause any statistically significant changes in the evaluated biochemical indices. In female rats, a statistically significant reduction in serum ALT activity was observed only at 660 mg/kg/day. Elevated levels of ALT enzyme, as opposed to lowered ones, have been conventionally associated with hepatocellular membrane injury. Accordingly, an isolated reduction in ALT does not constitute evidence of hepatocellular damage in the absence of other supporting findings.

The apparent difference between the acute and repeated-dose biochemical findings is also noteworthy. Acute administration of Vernolac at 2000 mg/kg resulted in elevated AST and ALT in males, whereas repeated administration at significantly lower daily doses of Vernolac for 28 days did not reproduce this pattern. This may indicate that the acute biochemical response was associated with exposure to the substantially higher single dose rather than progressive hepatic injury.

The liver and kidneys represent major organs involved in xenobiotic metabolism and elimination and are therefore important potential targets in systemic toxicity studies. No biochemical pattern consistent with renal impairment was identified, and histological examination demonstrated preserved glomerular, tubular, interstitial, and vascular architecture. Similarly, no histopathological evidence of hepatic injury was detected. The integrated biochemical and histopathological findings therefore provide no evidence of overt hepatotoxicity or nephrotoxicity following repeated Vernolac exposure at doses up to 660 mg/kg/day.

Histopathology represents an important component of repeated-dose toxicity assessment as it permits direct identification of treatment-related structural lesions in target organs. Histopathological examination was performed on all animals in the current study and no treatment related microscopic abnormalities were identified in the liver, spleen, kidneys, lungs, heart, or brain following either acute or repeated Vernolac exposure.

The present observations are broadly correlated with previous studies involving three component decoction containing N. sativa, H. indicus, and S. glabra. Repeated oral administration of this decoction at doses of 4 and 6 g/kg/day for three months was previously reported to cause no statistically significant changes in the evaluated biochemical or hematological parameters, body weight, food consumption, or histological architecture of major organs [36]. The same herbal formulation has also demonstrated long-term anti-hepatocarcinogenic activity during prolonged administration in Wistar rats [37]. Additionally, a separate study by Ratnasooriya et al. demonstrated that repeated oral administration of an aqueous stem extract of V. zeylanica at 2500 mg/kg body weight/day for 21 consecutive days did not result in significant alterations in serum AST or ALT levels in rats [45].

Overall, the acute and 28-day repeated-dose toxicity studies indicated that Vernolac was well tolerated at the tested doses. No mortality, treatment-related clinical signs, adverse effects on body weight, food or water intake, organ weights, or treatment-related histopathological lesions were observed. Transient elevations in AST and ALT were noted in males following acute administration; however, these changes were not accompanied by hepatic histopathological abnormalities and were not reproduced during repeated dosing.

In the 28-day repeated-dose study, 660 mg/kg/day was the highest tested dose and was not associated with evidence of overt systemic toxicity or treatment-related histopathological changes in the examined organs. Although a reduction in eosinophil counts was observed, this was not accompanied by other abnormalities in the hematological profile, clinical observations, body-weight progression, or organ histopathology. In the absence of corroborating functional or pathological changes, the observed reduction in eosinophils was considered an isolated hematological finding without sufficient evidence of adverse toxicological significance. Therefore, based on the overall weight of evidence and under the conditions of the present 28-day study, 660 mg/kg/day may be considered the NOAEL.

© All Rights Reserved.